News & Updates
Filter by Specialty:
AKI post-AMI tied to more serious kidney outcomes
Patients who develop acute kidney injury (AKI) following an acute myocardial infarction (AMI) have an elevated risk of more serious kidney outcomes including persistent reductions in estimated glomerular filtration rate (eGFR), end-stage renal disease (ESRD), or renal death, according to results of the PARADISE-MI trial.
AKI post-AMI tied to more serious kidney outcomes
19 Nov 2021
Subgroup findings boost dupilumab benefit for CRSwNP, comorbid asthma
In post hoc analyses of the phase III SINUS-24 and SINUS-52 trials, the monoclonal antibody dupilumab continued to render improvements for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), as well as among those with comorbid asthma regardless of asthma characteristics.
Subgroup findings boost dupilumab benefit for CRSwNP, comorbid asthma
18 Nov 2021
Dapagliflozin in COVID-19: Outcomes consistent regardless of kidney status
Secondary analysis of the DARE-19* trial presented at ASN Kidney Week 2021 has shown that the effect of dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 is consistent regardless of kidney disease status.
Dapagliflozin in COVID-19: Outcomes consistent regardless of kidney status
17 Nov 2021
Long-term TAF works against resistant HBV, poses no excess cardiovascular risk
Tenofovir alafenamide (TAF) shows sustained safety and efficacy in heavily pretreated patients with multidrug-resistant hepatitis B virus (HBV) through 3 years of treatment, albeit leading to elevations in cholesterol levels.
Long-term TAF works against resistant HBV, poses no excess cardiovascular risk
17 Nov 2021
Statins reduce hepatocellular carcinoma risk in cirrhotic patients
The risk of hepatocellular carcinoma (HCC) among patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis is low, reveals a recent study. In addition, dose-dependent statin can substantially lower the risk of HCC in patients with NASH cirrhosis.